The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.
CCNE1 Amplifications Tied to Racial Disparities in Serous Endometrial Cancer Outcomes
Julian Schink, MD, discusses a study evaluating racial differences in the mutational landscape of serous endometrial cancer, underscores the need for appropriate genomic testing and treatment for Black women with the disease, and explains the importance of racial representation across clinical trials.
Tumor Agnostic Role of TMB Biomarker Faces ChallengesAugust 18th 2022
Although tumor mutational burden is established as a clinically informative feature of tumors, its optimal use in therapeutic decision-making faces many challenges, and we are only beginning to fully understand its strengths and limitations.
Taking Action to Individualize Ovarian Cancer Care: Counseling Those with BRCA MutationsAugust 17th 2022
In this second episode of OncChats: Taking Action to Individualize Ovarian Cancer Care, John Nakayama, MD, and Christopher Morse, MD, discuss how to counsel patients with ovarian cancer whose tumors harbor BRCA mutations.
Liquid Biopsy Assay Expands Offerings to Include MRD, Disease Recurrence Detection in Early-Stage Breast and Lung CancerAugust 16th 2022
The Guardant Reveal assay has been expanded for the detection of minimal residual disease and disease recurrence in patients with early-stage breast cancer and lung cancer.
FDA Green Lights NGS-Based Companion Diagnostic for Trastuzumab Deruxtecan in HER2-Mutated NSCLCAugust 16th 2022
The FDA has approved the Oncomine Dx Target Test as a companion diagnostic to identify patients with NSCLC harboring an activating HER2 mutation who may derive clinical benefit from treatment with fam-trastuzumab deruxtecan-nxki.
Tumor Agnostic Approval Targets BRAF V600E–Mutant DiseaseAugust 15th 2022
Vivek Subbiah, MD, discusses the significance of the approval of dabrafenib plus trametinib for adult and pediatric patients 6 years or older with unresectable or metastatic BRAF V600E–mutant solid tumors and highlights future directions for tumor agnostic drug development.
FDA Approves VENTANA MMR RxDx To Identify dMMR Solid Tumors and as Companion Diagnostic for pMMR Endometrial CancerAugust 11th 2022
The FDA has expanded its approval of the VENTANA MMR RxDx panel to identify patients with mismatch repair–deficient solid tumors and as a companion diagnostic assay to determine eligibility for pembrolizumab as a treatment for patients with mismatch repair–proficient endometrial cancer.
Taking Action to Individualize Ovarian Cancer Care: Effect of BRCA on TreatmentAugust 10th 2022
In this first episode of OncChats: Taking Action to Individualize Ovarian Cancer Care, John Nakayama, MD, and Christopher Morse, MD, discuss how BRCA mutational status affects treatment decisions for patients with ovarian cancer.
Biomarker Testing Provides a Way Forward for Increasingly Accurate Lung Cancer Diagnosis and ManagementAugust 4th 2022
Giuseppe Lo Russo, MD, PhD, highlights the future role of liquid biopsy, the evolution of targeted therapies for KRAS G12C mutations, data to look forward to with EGFR-targeted agents, and the striking effects the COVID-19 pandemic has had on the mortality rates of patients with lung cancer.
PC14586 Shows Preliminary Activity, Safety in p53 Y220C–Mutant Solid TumorsJuly 28th 2022
The first-in-class p53 reactivator, PC14586, induced a response in approximately 1 of 4 patients with advanced solid tumors harboring p53 Y220C mutations and showcased an acceptable safety profile consisting primarily of grade 1 and 2 events.
Dr. Subbiah on the FDA Approval of Dabrafenib/Trametinib in BRAF V600E–Mutated Solid TumorsJuly 27th 2022
Vivek Subbiah, MD, discusses the FDA approval of dabrafenib plus trametinib for the treatment of patients with BRAF V600E–mutated unresectable or metastatic solid tumors.
Second-Line RGX-202-01 Plus FOLFIRI/Bevacizumab Shows Early Efficacy, Safety in KRAS-Mutant CRCJune 29th 2022
A second-line combination regimen comprised of RGX-202-01, FOLFIRI and bevacizumab demonstrated an encouraging efficacy signal and a favorable toxicity profile in patients with KRAS-mutant colorectal cancer.
Crenolanib Plus Chemotherapy Provides Long-Term Survival Benefit in FLT3-Mutant AMLJune 23rd 2022
Eunice Wang, MD, discusses the long-term results of a phase 2 trial investigating crenolanib plus chemotherapy in adult patients with newly diagnosed FLT3-mutant acute myeloid leukemia.
FDA Approves Dabrafenib Plus Trametinib for BRAF V600E–Mutated Unresectable or Metastatic Solid TumorsJune 22nd 2022
The FDA has granted an accelerated approval to dabrafenib plus trametinib for the treatment of adult and pediatric patients aged 6 years and older with unresectable or metastatic solid tumors harboring a BRAF V600E mutation who have progressed following previous treatment and who have no satisfactory alternative treatment options.
Repotrectinib Receives Breakthrough Therapy Designations in China for ROS1+ NSCLCJune 17th 2022
The China National Medical Products Administration’s Center for Drug Evaluation granted 2 breakthrough therapy designations to repotrectinib for the treatment of patients with ROS1-positive metastatic non–small cell lung cancer.
Sotorasib Produces Encouraging Antitumor Activity in Heavily Pretreated KRAS G12C–Mutated Pancreatic Cancer
Sotorasib demonstrated clinically meaningful activity and acceptable tolerability in heavily pretreated patients with KRAS G12C–mutated advanced pancreatic cancer, according to date from the single-arm, phase 1/2 CodeBreak 100 trial.
Quizartinib Plus Chemo Significantly Improves OS Vs Chemo Alone in Newly Diagnosed FLT3-ITD+ AMLJune 11th 2022
The addition of quizartinib to standard induction and consolidation chemotherapy and then continued as a single agent doubled median overall survival vs standard chemotherapy alone in patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.
Early Data Make B7-H3 a Checkpoint Contender in Prostate Cancer and BeyondJune 10th 2022
B7-H3, a member of the same protein family as PD-L1, has garnered attention as one of a slew of alternative targets riding the wave of success of immune checkpoint inhibitors in cancer immunotherapy.
FDA Approves FoundationOne CDx as a Companion Diagnostic for Entrectinib in ROS1+ and NTRK+ Cancers
The FDA has given the green light to FoundationOne CDx to identify patients with ROS1 fusion–positive non–small cell lung cancer or NTRK fusion–positive cancers who might be candidates for entrectinib.
Cobimetinib/Vemurafenib Combo Showcases Antitumor Activity in BRAF-Mutated Solid TumorsJune 7th 2022
A combination comprised of cobimetinib and vemurafenib demonstrated evidence of antitumor activity in patents with advanced solid tumors harboring BRAF V600E and other mutations who are not otherwise eligible to receive other FDA-approved therapies.
Larotrectinib Shows Continued Tumor-Agnostic Efficacy in Pediatric TRK Fusion+ Cancer
Pediatric patients with non–central nervous system, TRK fusion–positive cancers who were enrolled to the phase 1/2 SCOUT and phase 2 NAVIGATE trials and received larotrectinib continued to experience rapid and durable tumor-agnostic efficacy and prolonged survival.
Biomarker Analysis Confirms Benefit of Alpelisib Plus Fulvestrant Regardless of Mutation Status in HR+/HER- Breast CancerJune 5th 2022
Alpelisib plus fulvestrant demonstrated a clinical benefit regardless of gene mutation status in patients with hormone receptor–positive, HER2-negative advanced breast cancer, including those with FGFR1 or FGFR2 alterations.
Second-Line Pemigatinib May Provide PFS Benefit in Cholangiocarcinoma With FGFR2 Fusions/RearrangementsJune 2nd 2022
Second-line treatment with pemigatinib may be linked with prolonged progression-free survival compared with other systemic therapies in patients with cholangiocarcinoma harboring FGFR2 fusions or rearrangements.